Literature DB >> 3009852

Genetic analysis of the attenuation phenotype of poliovirus type 1.

T Omata, M Kohara, S Kuge, T Komatsu, S Abe, B L Semler, A Kameda, H Itoh, M Arita, E Wimmer.   

Abstract

Seven different recombinant viruses from the virulent Mahoney and the attenuated Sabin parental strains of type 1 poliovirus were constructed in vitro by using infectious cDNA clones. Monkey neurovirulence tests (lesion score, spread value, and incidence of paralysis) using these recombinant viruses revealed that the loci influencing attenuation were spread over several areas of the viral genome, including the 5' noncoding region. In vitro phenotypic marker tests corresponding to temperature sensitivity of growth (rct marker), plaque size, and dependency of growth on bicarbonate concentration (d marker) were performed to identify the genomic loci of these determinants and to investigate their correlation with attenuation. Determinants of temperature sensitivity mapped to many areas of the viral genome and expressed strong but not perfect correlation with attenuation. Recombinant viruses with Sabin-derived capsid proteins showed a small-plaque phenotype, and their growth was strongly dependent on bicarbonate concentration, suggesting that these determinants map to the genomic region encoding the viral capsid proteins. Plaque size and the d marker, however, were found to be poor indicators of attenuation. Moreover, virion surface characteristics such as immunogenicity and antigenicity had little or no correlation with neurovirulence. Nevertheless, viruses carrying Sabin-derived capsid proteins had an apparent tendency to exhibit less neurovirulence in tests on monkeys compared with recombinants carrying Mahoney-derived capsid proteins. Our results suggest that the extent of viral multiplication in the central nervous system of the test animals might be one of the most important factors determining neurovirulence. Moreover, we conclude that the expression of the attenuated phenotype of the Sabin 1 strain of poliovirus is the result of several different biological characteristics. Finally, none of the in vitro phenotypic markers alone can serve as a good indicator of neurovirulence or attenuation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009852      PMCID: PMC252919     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Persistence of immunity after administration of formalin-treated poliovirus vaccine.

Authors:  J E SALK
Journal:  Lancet       Date:  1960-10-01       Impact factor: 79.321

2.  Investigation of the structure of polio- and human rhinovirions through the use of selective chemical reactivity.

Authors:  K Lonberg-Holm; B E Butterworth
Journal:  Virology       Date:  1976-05       Impact factor: 3.616

3.  Iodination of poliovirus capsid proteins.

Authors:  T W Beneke; K O Habermehl; W Diefenthal; M Buchholz
Journal:  J Gen Virol       Date:  1977-02       Impact factor: 3.891

4.  In vitro phenotypic markers of a poliovirus recombinant constructed from infectious cDNA clones of the neurovirulent Mahoney strain and the attenuated Sabin 1 strain.

Authors:  M Kohara; T Omata; A Kameda; B L Semler; H Itoh; E Wimmer; A Nomoto
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

5.  Neurovirulence of the intertypic poliovirus recombinant v3/a1-25: characterization of strains isolated from the spinal cord of diseased monkeys and evaluation of the contribution of the 3' half of the genome.

Authors:  V I Agol; S G Drozdov; M P Frolova; V P Grachev; M S Kolesnikova; V G Kozlov; N M Ralph; L I Romanova; E A Tolskaya; E G Viktorova
Journal:  J Gen Virol       Date:  1985-02       Impact factor: 3.891

6.  Thermosensitive block of the Sabin strain of poliovirus type I.

Authors:  M Fiszman; M Reynier; D Bucchini; M Girard
Journal:  J Virol       Date:  1972-12       Impact factor: 5.103

7.  Mechanism of plaque inhibition of poliovirus possessing the d marker.

Authors:  C Wallis; J L Melnick
Journal:  J Gen Virol       Date:  1968-12       Impact factor: 3.891

8.  Cloned infectious complementary DNA of the poliovirus Sabin 1 genome: biochemical and biological properties of the recovered virus.

Authors:  T Omata; M Kohara; Y Sakai; A Kameda; N Imura; A Nomoto
Journal:  Gene       Date:  1984-12       Impact factor: 3.688

9.  Construction and properties of intertypic poliovirus recombinants: first approximation mapping of the major determinants of neurovirulence.

Authors:  V I Agol; V P Grachev; S G Drozdov; M S Kolesnikova; V G Kozlov; N M Ralph; L I Romanova; E A Tolskaya; A V Tyufanov; E G Viktorova
Journal:  Virology       Date:  1984-07-15       Impact factor: 3.616

10.  Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome.

Authors:  D M Evans; G Dunn; P D Minor; G C Schild; A J Cann; G Stanway; J W Almond; K Currey; J V Maizel
Journal:  Nature       Date:  1985 Apr 11-17       Impact factor: 49.962

View more
  78 in total

1.  Mapping the genetic determinants of pathogenicity and plaque phenotype in swine vesicular disease virus.

Authors:  T Kanno; D Mackay; T Inoue; G Wilsden; M Yamakawa; R Yamazoe; S Yamaguchi; J Shirai; P Kitching; Y Murakami
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

3.  Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses.

Authors:  J J Holland; J C de la Torre; D K Clarke; E Duarte
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

4.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Tissue-specific replicating capacity of a chimeric poliovirus that carries the internal ribosome entry site of hepatitis C virus in a new mouse model transgenic for the human poliovirus receptor.

Authors:  Akiko Yanagiya; Seii Ohka; Noriyasu Hashida; Masahito Okamura; Choji Taya; Nobuhiko Kamoshita; Kuniko Iwasaki; Yukari Sasaki; Hiromichi Yonekawa; Akio Nomoto
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; F Delpeyroux; M Tardy-Panit; J Balanant; M Combiescu; A A Combiescu; S Guillot; R Crainic
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Transgenic mice susceptible to poliovirus.

Authors:  S Koike; C Taya; T Kurata; S Abe; I Ise; H Yonekawa; A Nomoto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

10.  Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons.

Authors:  Cara C Burns; Ray Campagnoli; Jing Shaw; Annelet Vincent; Jaume Jorba; Olen Kew
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.